ATIM-23. ANTI-CD27 AGONIST ANTIBODY VARLILUMAB IN COMBINATION WITH NIVOLUMAB FOR RECURRENT GLIOBLASTOMA (rGBM): PHASE 2 CLINICAL TRIAL RESULTS

CD27 is a key immunostimulatory molecule that enhances T cell survival, activation and effector function, as well as proliferation and cytotoxic activity of NK cells. Preclinical studies demonstrate synergistic activity of PD-(L)1 blockade and varlilumab, an anti-CD27 agonist monoclonal antibody. In...

全面介紹

Na minha lista:
書目詳細資料
發表在:Neuro Oncol
Main Authors: Reardon, David, Kaley, Thomas, Iwamoto, Fabio, Baehring, Joachim, Subramaniam, Deepa, Rawls, Tracey, He, Yi, Keler, Tibor, Yellin, Michael
格式: Artigo
語言:Inglês
出版: Oxford University Press 2018
主題:
Abstracts
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216130/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.018
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍